Your session is about to expire
← Back to Search
NB003 for Solid Cancer
Study Summary
This trial is testing a new drug, NB003, to see if it is safe and tolerated by people with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I received targeted radiation for symptom relief within the last week.I have not had major surgery in the last 4 weeks.I am 18 years old or older.I haven't had cancer treatment in the last 2-3 weeks.I have provided a sample of my tumor for testing.I am not taking any strong CYP3A4 inhibitors or inducers.I do not have active brain metastases, meningitis, hepatitis B, hepatitis C, or HIV.My organs and bone marrow are working well.My cancer is advanced and cannot be removed by surgery.I am fully active or can carry out light work.I am using acid-reducing medication and cannot stop it 2 weeks before starting the trial.
- Group 1: Dose Escalation Phase and Dose Expansion Phase
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How extensive is the population sample participating in this research endeavor?
"That is correct. Clinicaltrials.gov reveals that this clinical trial opened for enrollment on August 6th 2021 and was last edited on January 29th 2022. The research team is looking to recruit 36 patients from a single site."
Are there any attendant risks when using NB003 tablets?
"Due to a lack of supporting evidence, our team at Power assigned NB003 tablets a score of 1 on the safety scale. This is due to it being part of Phase 1 trials which have limited clinical data confirming its efficacy and safety."
What results are researchers expecting to see from this clinical experiment?
"This trial, which will take up to 2 years for the first subject enrolled, aims to observe any adverse effects. Other objectives include monitoring duration of response (DOR), objective response rate (ORR) and area under the curve (AUC)."
Are there still vacancies available to participate in this research project?
"That is correct. On clinicaltrials.gov, it states that this study, which was published on the 6th of August 2021, is still seeking participants. A total of 36 patients are to be enrolled across a single research centre."
Share this study with friends
Copy Link
Messenger